Merge Talks Between The EVERY Co and Onego Bio
The EVERY Co and Onego Bio were discussing a potential $400m merger before negotiations fell apart, according to court documents.
Alt-egg startups The EVERY Company and Onego Bio aimed to create a new company with a valuation of $400m, but talks failed and Onego Bio sued its rival.
Patent Dispute
The EVERY Co has urged a court in Wisconsin to dismiss a lawsuit from Onego Bio seeking to invalidate one of EVERY's patents, which covers the production of ovalbumin via precision fermentation.
- The EVERY Co uses yeast (Komagataella phaffii) as its host microorganism.
- Onego Bio uses fungus (Trichoderma reesei).
The dispute centers on whether Onego is infringing a “foundational” patent (‘784) from The EVERY Co covering ovalbumin expression in a range of hosts.
In summary: The EVERY Co and Onego Bio merger talks failed.
More News
- ‘Elsbeth’ Costume Designer Dan Lawson Talks Recreating ‘My Fair Lady’ Outfits for Halloween Episode (Exclusive)
- V Levels must build on the best of BTECs, not erase them
- Billie Eilish Calls on Billionaires to Do More for People in Need
- Microsoft’s agent platform play
- NBA star LaMelo Ball fined $35K for obscene gesture
- ASX Climbs on Bank, Gold Miner Gains - Sharecafe